RS54738B1 - Agensi koji vrše reverziju antikoagulanta - Google Patents

Agensi koji vrše reverziju antikoagulanta

Info

Publication number
RS54738B1
RS54738B1 RS20160318A RSP20160318A RS54738B1 RS 54738 B1 RS54738 B1 RS 54738B1 RS 20160318 A RS20160318 A RS 20160318A RS P20160318 A RSP20160318 A RS P20160318A RS 54738 B1 RS54738 B1 RS 54738B1
Authority
RS
Serbia
Prior art keywords
compound
dap
pharmaceutically acceptable
subject
factor
Prior art date
Application number
RS20160318A
Other languages
English (en)
Serbian (sr)
Inventor
Solomon S Steiner
Bryan E Laulicht
Sasha H Bakhru
Edith Mathiowitz
Original Assignee
Perosphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47430065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS54738(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Perosphere Inc filed Critical Perosphere Inc
Publication of RS54738B1 publication Critical patent/RS54738B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20160318A 2011-11-29 2012-11-29 Agensi koji vrše reverziju antikoagulanta RS54738B1 (sr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161564559P 2011-11-29 2011-11-29
US201261614292P 2012-03-22 2012-03-22
US201261641698P 2012-05-02 2012-05-02
US201261666291P 2012-06-29 2012-06-29
EP12806229.6A EP2785700B1 (en) 2011-11-29 2012-11-29 Anticoagulant reversal agents
PCT/US2012/066938 WO2013082210A1 (en) 2011-11-29 2012-11-29 Anticoagulant reversal agents

Publications (1)

Publication Number Publication Date
RS54738B1 true RS54738B1 (sr) 2016-10-31

Family

ID=47430065

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160318A RS54738B1 (sr) 2011-11-29 2012-11-29 Agensi koji vrše reverziju antikoagulanta

Country Status (34)

Country Link
US (5) US9522892B2 (https=)
EP (1) EP2785700B1 (https=)
JP (1) JP6134731B2 (https=)
KR (1) KR101892330B1 (https=)
CN (1) CN104080772B (https=)
AP (1) AP2014007662A0 (https=)
AR (1) AR089020A1 (https=)
AU (1) AU2012345975B2 (https=)
BR (1) BR112014012892B1 (https=)
CA (1) CA2856540C (https=)
CL (1) CL2014001399A1 (https=)
CO (1) CO6990738A2 (https=)
CR (1) CR20140310A (https=)
CY (1) CY1117414T1 (https=)
DK (1) DK2785700T3 (https=)
EA (1) EA027603B1 (https=)
EC (1) ECSP14006696A (https=)
ES (1) ES2569674T3 (https=)
HR (1) HRP20160513T1 (https=)
HU (1) HUE027452T2 (https=)
IL (1) IL232788B (https=)
ME (1) ME02424B (https=)
MX (1) MX349514B (https=)
PE (1) PE20141295A1 (https=)
PH (1) PH12014501176A1 (https=)
PL (1) PL2785700T3 (https=)
PT (1) PT2785700E (https=)
RS (1) RS54738B1 (https=)
SG (1) SG11201402713WA (https=)
SI (1) SI2785700T1 (https=)
SM (1) SMT201600161B (https=)
UA (1) UA116336C2 (https=)
WO (1) WO2013082210A1 (https=)
ZA (1) ZA201404793B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9999690B2 (en) 2013-11-08 2018-06-19 Perosphere Pharmaceuticals Inc. Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
KR102483020B1 (ko) 2016-03-28 2023-01-04 인사이트 코포레이션 Tam 저해제로서의 피롤로트리아진 화합물
MA50655B1 (fr) 2017-09-27 2021-11-30 Incyte Corp Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
WO2019094959A1 (en) * 2017-11-13 2019-05-16 Fernandez Joss Reconstitution of post mortem circulation, specialized methods and procedures
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
US11716989B2 (en) 2019-04-16 2023-08-08 Maximum Fidelity Surgical Simulations, LLC Cadaver preservation systems and methods
US11915610B2 (en) 2019-05-15 2024-02-27 Maximum Fidelity Surgical Simulations, LLC Cadaverous heart model
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN118684672A (zh) 2023-03-24 2024-09-24 陕西麦科奥特科技有限公司 一种抗凝逆转剂及其制备方法和应用
CN117624137A (zh) * 2023-12-04 2024-03-01 中国药科大学 三嗪骨架小分子肝素逆转剂及其制备方法与用途
US20250389737A1 (en) * 2024-06-20 2025-12-25 Instrumentation Laboratory Company FACTOR Xa REAGENT
EP4667582A1 (en) * 2024-06-20 2025-12-24 Instrumentation Laboratory Company Factor xa reagent
CN121622691A (zh) * 2024-08-30 2026-03-10 陕西麦科奥特医药科技股份有限公司 使用抗凝逆转剂治疗抗凝剂导致的出血的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678157A (en) * 1968-10-23 1972-07-18 Oreal Hair treatment compositions containing polycondensable compounds
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US6069232A (en) * 1995-10-02 2000-05-30 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
US6080852A (en) 1996-06-27 2000-06-27 The Perkin-Elmer Corporation 4,7-dichlororhodamine dyes
WO1998016547A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
JP2001519806A (ja) * 1997-04-07 2001-10-23 アクシス ファーマシューティカルズ,インコーポレイティド セリンプロテアーゼ活性、特にトリプターゼ活性に関連する疾病を処理するための化合物及び組成物
FR2781221B1 (fr) * 1998-07-17 2000-10-13 Lafon Labor Piperazinones substituees en alpha
CA2348740A1 (en) * 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
NZ514877A (en) 1999-05-19 2004-10-29 Pharmacia Corp Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
EP1377554A1 (en) * 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
CA2405684A1 (en) 2000-04-17 2001-10-25 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
AU2001275857A1 (en) * 2000-06-29 2002-01-14 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
EP1438292A1 (en) 2001-10-03 2004-07-21 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
US20060148734A1 (en) * 2002-03-27 2006-07-06 Patrick Camilleri Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
JPWO2003099324A1 (ja) * 2002-05-23 2005-09-22 中外製薬株式会社 組織因子阻害剤中和剤及び活性型血液凝固第vii因子製剤中和剤
GB0214122D0 (en) 2002-06-19 2002-07-31 Eastman Kodak Co High contrast photographic element containing a polyhydrazide nucleating agent
SE0400014D0 (sv) * 2004-01-08 2004-01-08 Astrazeneca Ab Heterocyclic derivatives
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
WO2008105441A1 (ja) * 2007-02-27 2008-09-04 Ajinomoto Co., Inc. リン吸収抑制活性を有するポリアミノ酸化合物及びリン吸収抑制剤
EP2915564B1 (en) * 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
GB2476643B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
PE20140964A1 (es) 2011-03-30 2014-08-17 Boehringer Ingelheim Int Antidotos anticoagulantes

Also Published As

Publication number Publication date
PH12014501176B1 (en) 2014-09-01
IL232788A0 (en) 2014-08-03
PE20141295A1 (es) 2014-10-01
PH12014501176A1 (en) 2014-09-01
IL232788B (en) 2018-05-31
NZ625337A (en) 2016-11-25
ZA201404793B (en) 2015-04-29
CN104080772A (zh) 2014-10-01
SMT201600161B (it) 2016-07-01
US9877961B2 (en) 2018-01-30
PT2785700E (pt) 2016-06-02
AU2012345975B2 (en) 2016-12-15
EP2785700B1 (en) 2016-03-09
EA201490823A1 (ru) 2015-01-30
SG11201402713WA (en) 2014-06-27
SI2785700T1 (sl) 2016-09-30
AU2012345975A1 (en) 2014-05-29
ES2569674T3 (es) 2016-05-12
EA027603B1 (ru) 2017-08-31
CA2856540A1 (en) 2013-06-06
PL2785700T3 (pl) 2016-09-30
CR20140310A (es) 2014-08-20
US20240366592A1 (en) 2024-11-07
CY1117414T1 (el) 2017-04-26
CO6990738A2 (es) 2014-07-10
KR20140107259A (ko) 2014-09-04
UA116336C2 (uk) 2018-03-12
EP2785700A1 (en) 2014-10-08
BR112014012892A2 (pt) 2017-06-13
DK2785700T3 (en) 2016-06-13
US20180207152A1 (en) 2018-07-26
US20170056396A1 (en) 2017-03-02
JP6134731B2 (ja) 2017-05-24
AR089020A1 (es) 2014-07-23
US9522892B2 (en) 2016-12-20
JP2014534270A (ja) 2014-12-18
CA2856540C (en) 2018-04-03
HRP20160513T1 (hr) 2016-07-15
HK1202858A1 (en) 2015-10-09
WO2013082210A1 (en) 2013-06-06
US20130137702A1 (en) 2013-05-30
CN104080772B (zh) 2016-10-05
MX349514B (es) 2017-08-02
HUE027452T2 (en) 2016-09-28
ME02424B (me) 2016-09-20
US20210169874A1 (en) 2021-06-10
BR112014012892B1 (pt) 2022-12-20
ECSP14006696A (es) 2015-06-30
AP2014007662A0 (en) 2014-05-31
MX2014006349A (es) 2014-09-04
BR112014012892A8 (pt) 2021-06-08
KR101892330B1 (ko) 2018-08-27
CL2014001399A1 (es) 2014-11-03

Similar Documents

Publication Publication Date Title
US20240366592A1 (en) Anticoagulant reversal agents
ES2384116T3 (es) Sales y polimorfos farmacéuticos de N-(5-cloro-2-piridinil)-2-[[4-[(dimetilamino)iminometil]benzoil]amino]-5-metoxi-benzamida, un inhibidor del factor XA
CN1078070C (zh) 苯并噻吩衍生物在制备抑制凝血酶药物中的用途
US20110183906A1 (en) Factor ix conjugates with extended half-lives
CN100509799C (zh) 一种合成非手性,非肽类的抗凝血酶抑制剂的方法
TW200911787A (en) New aza-bicyclohexane compounds useful as inhibitors of thrombin
US20130296245A1 (en) Prolinamiade derivatives as thrombin inhibitor, prepraration method and application thereof
OA16905A (en) Anticoagulant reversal agents.
HK1202858B (en) Anticoagulant reversal agents
CN103880797B (zh) 苯并呋喃类化合物及其医药用途
EA007300B1 (ru) Некоторые производные 1-(d-циклопропилглицинил)-4-(пиперидин-4-ил) пиперазина в качестве ингибиторов серинпротеазы фактора ха
JP2010532767A (ja) 光学活性のN−(α−メルカプトプロピオニル)グリシン
NZ625337B2 (en) Anticoagulant reversal agents
CN105367622B (zh) 一种阿加曲班化合物
CN100526293C (zh) 2,5-二羟基苯磺酸镁及其水合物
Hens et al. The Role of Kinetics in High Throughput Screening for Drugs